Huntington's disease and striatal signaling

Frontiers in Neuroanatomy

Volumn , Issue AUG, 2011, Pages 1-16

  Roze, Emmanuel ^a,b   Cahill, Emma ^a   Martin, Elodie ^a   Bonnet, Cecilia ^c   Vanhoutte, Peter ^a   Betuing, Sandrine ^a   Caboche, Jocelyne ^a  

^a Groupe Enzymologie Moléculaire et Fonctionnelle   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Excitotoxicity; Huntingtin; Mitochondrial dysfunctions; Polyglutamine; Transcriptional deregulation

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; DOPAMINE; HISTONE H3; HUNTINGTIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PHOSPHOPROTEIN DARPP 32; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2;

CHOREA; CHROMATIN ASSEMBLY AND DISASSEMBLY; COGNITIVE DEFECT; CORPUS STRIATUM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC TRANSMISSION; ENERGY DEFICIT; ENERGY METABOLISM; EXCITOTOXICITY; GENE MUTATION; GENETICS; HUMAN; HUNTINGTON CHOREA; MENTAL DISEASE; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NEUROPATHOLOGY; NONHUMAN; PROTEIN AGGREGATION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; SYNAPTIC DYSFUNCTION; SYNAPTIC TRANSMISSION; TRANSCRIPTION REGULATION; TRANSCRIPTIONAL DYSREGULATION;

EID: 84863008363     PISSN: 16625129     EISSN: None     Source Type: Journal    
DOI: 10.3389/fnana.2011.00055     Document Type: Review

References (266)

1. Alford, R. L., Ashizawa, T., Jankovic, J., Caskey, C. T., and Richards, C. S. (1996). Molecular detection of new mutations, resolution of ambiguous results and complex genetic counseling issues in Huntington disease. Am. J. Med. Genet. 66, 281-286.
2. Andresen, J. M., Gayan, J., Cherny, S. S., Brocklebank, D., Alkorta-Aranburu, G., Addis, E. A., Cardon, L. R., Housman, D. E., and Wexler, N. S. (2007). Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds. J. Med. Genet. 44, 44-50.
3. Andrew, S. E., Goldberg, Y. P., Kremer, B., Telenius, H., Theilmann, J., Adam, S., Starr, E., Squitieri, F., Lin, B., Kalchman, M. A., Graham, R. K., and Hayden, M. R. (1993). The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease. Nat. Genet. 4, 398-403.
4. Anne, S. L., Saudou, F., and Humbert, S. (2007). Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in neurons. J. Neurosci. 27, 7318-7328.
5. Apostol, B. L., Simmons, D. A., Zuccato, C., Illes, K., Pallos, J., Casale, M., Conforti, P., Ramos, C., Roarke, M., Kathuria, S., Cattaneo, E., Marsh, J. L., and Thompson, L. M. (2008). CEP-1347 reduces mutant huntingtin-associated neu-rotoxicity and restores BDNF levels in R6/2 mice. Mol. Cell. Neurosci. 39, 8-20.
6. Arango, M., Holbert, S., Zala, D., Brouillet, E., Pearson, J., Regulier, E., Thakur, A. K., Aebischer, P., Wetzel, R., Deglon, N., and Neri, C. (2006). CA150 expression delays striatal cell death in overexpression and knock-in conditions for mutant huntingtin neurotoxicity. J. Neurosci. 26, 4649-4659.
7. Arenas, J., Campos, Y., Ribacoba, R., Martin, M. A., Rubio, J. C., Ablanedo, P., and Cabello, A. (1998). Complex I defect in muscle from patients with Huntington's disease. Ann. Neurol. 43, 397-400.
8. Arnulf, I., Nielsen, J., Lohmann, E., Schiefer, J., Wild, E., Jennum, P., Konofal, E., Walker, M., Oudiette, D., Tabrizi, S., and Durr, A. (2008). Rapid eye movement sleep disturbances in Huntington disease. Arch. Neurol. 65, 482-488.
9. Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., and Finkbeiner, S. (2004). Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 431, 805-810.
10. Augood, S. J., Faull, R. L., and Emson, P. C. (1997). Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease. Ann. Neurol. 42, 215-221.
11. Augood, S. J., Faull, R. L., Love, D. R., and Emson, P. C. (1996). Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: a detailed cellular in situ hybridization study. Neuroscience 72, 1023-1036.
12. Aziz, N. A., Van Der Burg, J. M., Landwehrmeyer, G. B., Brundin, P., Stijnen, T., and Roos, R. A. (2008). Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 71, 1506-1513.
13. Bae, B. I., Xu, H., Igarashi, S., Fujimuro, M., Agrawal, N., Taya, Y., Hayward, S. D., Moran, T. H., Montell, C., Ross, C. A., Snyder, S. H., and Sawa, A. (2005). p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47, 29-41.
14. Bamford, K. A., Caine, E. D., Kido, D. K., Cox, C., and Shoulson, I. (1995). A prospective evaluation of cognitive decline in early Huntington's disease: functional and radiographic correlates. Neurology 45, 1867-1873
15. Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., and Martin, J. B. (1986). Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321, 168-171.
16. Behrens, P. F., Franz, P., Woodman, B., Lindenberg, K. S., and Landwehrmeyer, G. B.(2002). Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. Brain 125, 1908-1922.
17. Bence, N. F., Sampat, R. M., and Kopito, R. R. (2001). Impairment of the ubiquitin-proteasome system by protein aggregation. Science 292, 1552-1555.
18. Benchoua, A., Trioulier, Y., Diguet, E., Malgorn, C., Gaillard, M. C., Dufour, N., Elalouf, J. M., Krajewski, S., Hantraye, P., Deglon, N., and Brouillet, E. (2008). Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II. Hum. Mol. Genet. 17, 1446-1456.
19. Benchoua, A., Trioulier, Y., Zala, D., Gaillard, M. C., Lefort, N., Dufour, N., Saudou, F., Elalouf, J. M., Hirsch, E., Hantraye, P., Deglon, N., and Brouillet, E. (2006). Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin. Mol. Biol. Cell 17, 1652-1663.
20. Bennett, E. J., Shaler, T. A., Woodman, B., Ryu, K. Y., Zaitseva, T. S., Becker, C. H., Bates, G. P., Schulman, H., and Kopito, R. R. (2007). Global changes to the ubiquitin system in Huntington's disease. Nature 448, 704-708.
21. Borovecki, F., Lovrecic, L., Zhou, J., Jeong, H., Then, F., Rosas, H. D., Hersch, S. M., Hogarth, P., Bouzou, B., Jensen, R. V., and Krainc, D. (2005). Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 102, 11023-11028.
22. Borrell-Pages, M., Canals, J. M., Cordelieres, F. P., Parker, J. A., Pineda, J. R., Grange, G., Bryson, E. A., Guillermier, M., Hirsch, E., Hantraye, P., Cheetham, M. E., Neri, C., Alberch, J., Brouillet, E., Saudou, F., and Humbert, S. (2006a). Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J. Clin. Invest. 116, 1410-1424.
23. Borrell-Pages, M., Zala, D., Humbert, S., and Saudou, F. (2006b). Huntington's disease: from huntingtin function and dysfunction to therapeutic strategies. Cell. Mol. Life Sci. 63, 2642-2660.
24. Boutell, J. M., Thomas, P., Neal, J. W., Weston, V. J., Duce, J., Harper, P. S., and Jones, A. L. (1999). Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. Hum. Mol. Genet. 8, 1647-1655.
25. Brami-Cherrier, K., Roze, E., Girault, J. A., Betuing, S., and Caboche, J. (2009). Role of the ERK/MSK1 signalling pathway in chromatin remodelling and brain responses to drugs of abuse. J. Neurochem. 108, 1323-1335.
26. Brami-Cherrier, K., Valjent, E., Herve, D., Darragh, J., Corvol, J. C., Pages, C., Arthur, S. J., Girault, J. A., and Caboche, J. (2005). Parsing molecular and behavioral effects of cocaine in mitogen-and stress-activated protein kinase-1-deficient mice. J. Neurosci. 25, 11444-11454.
27. Brouillet, E., Conde, F., Beal, M. F., and Hantraye, P. (1999). Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59, 427-468.
28. Brouillet, E., Guyot, M. C., Mittoux, V., Altairac, S., Conde, F., Palfi, S., and Hantraye, P. (1998). Partial inhibition of brain succinate dehydrogenase by 3-nitropropionic acid is sufficient to initiate striatal degeneration in rat. J. Neurochem. 70, 794-805.
29. Busse, M. E., Wiles, C. M., and Rosser, A. E. (2009). Mobility and falls in people with Huntington's disease. J. Neurol. Neurosurg. Psychiatr. 80, 88-90.
30. Caine, E. D., Ebert, M. H., and Weingartner, H. (1977). An outline for the analysis of dementia. The memory disorder of Huntingtons disease. Neurology 27, 1087-1092.
31. Caine, E. D., Hunt, R. D., Weingartner, H., and Ebert, M. H. (1978). Huntington's dementia. Clinical and neuropsychological features. Arch. Gen. Psychiatry 35, 377-384.
32. Caine, E. D., and Shoulson, I. (1983). Psychiatric syndromes in Huntington's disease. Am. J. Psychiatry 140, 728-733.
33. Canals, J. M., Pineda, J. R., Torres-Peraza, J. F., Bosch, M., MartinIbanez, R., Munoz, M. T., Mengod, G., Ernfors, P., and Alberch, J. (2004). Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J. Neurosci. 24, 7727-7739.
34. Carella, F., Scaioli, V., Ciano, C., Binelli, S., Oliva, D., and Girotti, F. (1993). Adult onset myoclonic Huntington's disease. Mov. Disord. 8, 201-205.
35. Carmichael, J., Chatellier, J., Woolfson, A., Milstein, C., Fersht, A. R., and Rubinsztein, D. C. (2000). Bacterial and yeast chaperones reduce both aggregate formation and cell death in mammalian cell models of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 97, 9701-9705.
36. Caviston, J. P., and Holzbaur, E. L. (2009). Huntingtin as an essential integrator of intracellular vesicular trafficking. Trends Cell Biol. 19, 147-155.
37. Caviston, J. P., Ross, J. L., Antony, S. M., Tokito, M., and Holzbaur, E. L. (2007). Huntingtin facilitates dynein/dynactin-mediated vesicle transport. Proc. Natl. Acad. Sci. U.S.A. 104, 10045-10050.
38. Cepeda, C., Ariano, M. A., Calvert, C. R., Flores-Hernandez, J., Chandler, S. H., Leavitt, B. R., Hayden, M. R., and Levine, M. S. (2001). NMDA receptor function in mouse models of Huntington disease. J. Neurosci. Res. 66, 525-539.
39. Cha, J. H. (2007). Transcriptional signatures in Huntington's disease. Prog. Neurobiol. 83, 228-248.
40. Cha, J. H., Frey, A. S., Alsdorf, S. A., Kerner, J. A., Kosinski, C. M., Mangiarini, L., Penney, J. B. Jr., Davies, S. W., Bates, G. P., and Young, A. B. (1999). Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354, 981-989.
41. Cha, J. H., Kosinski, C. M., Kerner, J. A., Alsdorf, S. A., Mangiarini, L., Davies, S. W., Penney, J. B., Bates, G. P., and Young, A. B. (1998). Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene. Proc. Natl. Acad. Sci. U.S.A. 95, 6480-6485.
42. Charvin, D., Roze, E., Perrin, V., Deyts, C., Betuing, S., Pages, C., Regulier, E., Luthi-Carter, R., Brouillet, E., Deglon, N., and Caboche, J. (2008). Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo. Neurobiol. Dis. 29, 22-29.
43. Charvin, D., Vanhoutte, P., Pages, C., Borrelli, E., and Caboche, J. (2005). Unraveling a role for dopamine in Huntington's disease: the dual role of reactive oxygen species and D2 receptor stimulation. Proc. Natl. Acad. Sci. U.S.A. 102, 12218-12223.
44. Chopra, V., Fox, J. H., Lieberman, G., Dorsey, K., Matson, W., Waldmeier, P., Housman, D. E., Kazantsev, A., Young, A. B., and Hersch, S. (2007). A small molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse. Proc. Natl. Acad. Sci. U.S.A. 104, 16685-16689.
45. Colin, E., Zala, D., Liot, G., Rangone, H., Borrel-Pagès, M., Li, X. J., Saudou, F., and Humbert, S. (2008). Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J. 27, 2124-2134.
46. Cui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., and Krainc, D.(2006).Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell. 127, 59-69.
47. Cull-Candy, S., Brickley, S., and Farrant, M. (2001). NMDA receptor subunits: diversity, development and disease. Curr. Opin. Neurobiol. 11, 327-335.
48. Cummings, J. L. (1995). Behavioral and psychiatric symptoms associated with Huntington's disease. Adv. Neurol. 65, 179-186.
49. Cummings, J. L., and Cunningham, K. (1992). Obsessive-compulsive disorder in Huntington's disease. Biol. Psychiatry 31, 263-270.
50. Cyr, M., Beaulieu, J. M., Laakso, A., Sotnikova, T. D., Yao, W. D., Bohn, L. M., Gainetdinov, R. R., and Caron, M. G. (2003). Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc. Natl. Acad. Sci. U.S.A. 100, 11035-11040.
51. Cyr, M., Sotnikova, T. D., Gainetdinov, R. R., and Caron, M. G. (2006). Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin. FASEB J. 20, 2541-2543.
52. Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., and Bates, G. P. (1997). Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90, 537-548.
53. Davis, M. B., Bateman, D., Quinn, N. P., Marsden, C. D., and Harding, A. E. (1994). Mutation analysis in patients with possible but apparently sporadic Huntington's disease. Lancet 344, 714-717.
54. Dawbarn, D., De Quidt, M. E., and Emson, P. C. (1985). Survival of basal ganglia neuropeptide Y-somatostatin neurones in Huntington's disease. Brain Res. 340, 251-260.
55. De Almeida, L. P., Ross, C. A., Zala, D., Aebischer, P., and Deglon, N.(2002).Lentiviral-mediated delivery of mutant huntingtin in the striatum of rats induces a selective neuropathology modulated by polyglutamine repeat size, huntingtin expression levels, and protein length. J. Neurosci. 22, 3473-3483.
56. Del Toro, D., Canals, J. M., Gines, S., Kojima, M., Egea, G., and Alberch, J.(2006).Mutant huntingtin impairs the post-Golgi trafficking of brain-derived neurotrophic factor but not its Val66Met polymorphism. J. Neurosci. 26, 12748-12757.
57. Desplats, P. A., Kass, K. E., Gilmartin, T., Stanwood, G. D., Woodward, E. L., Head, S. R., Sutcliffe, J. G., and Thomas, E. A. (2006). Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J.Neurochem.96, 743-757.
58. Deyts, C., Galan-Rodriguez, B., Mar-tin, E., Bouveyron, N., Roze, E., Charvin, D., Caboche, J., and Betuing, S. (2009). Dopamine D2 receptor stimulation potentiatesPolyQ-Huntingtin-induced mouse striatal neuron dysfunctions viaRho/ROCK-II activation. PLoS ONE 4,e8287. doi: 10.1371/journal.pone.0008287
59. Di Maio, L., Squitieri, F., Napolitano, G., Campanella, G., Trofatter, J. A., and Conneally, P. M. (1993). Onset symptoms in 510 patients with Huntington's disease. J. Med. Genet. 30, 289-292.
60. DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., and Aronin, N. (1997). Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277, 1990-1993.
61. Diguet, E., Petit, F., Escartin, C., Cambon, K., Bizat, N., Dufour, N., Hantraye, P., Deglon, N., and Brouillet, E. (2009). Normal aging modulates the neurotoxicity of mutant huntingtin. PLoS ONE 4, e4637. doi: 10.1371/journal.pone.0004637
62. Dingledine, R., Borges, K., Bowie, D., and Traynelis, S. F. (1999). The glutamate receptor ion channels. Pharmacol. Rev. 51, 7-61.
63. Djousse, L., Knowlton, B., Cupples, L. A., Marder, K., Shoulson, I., and Myers, R. H. (2002). Weight loss in early stage of Huntington's disease. Neurology 59, 1325-1330.
64. Dompierre, J. P., Godin, J. D., Charrin, B. C., Cordelieres, F. P., King, S. J., Humbert, S., and Saudou, F. (2007). Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J. Neurosci. 27, 3571-3583.
65. Dragatsis, I., Dietrich, P., and Zeitlin, S. (2000). Expression of the Huntingtinassociated protein1 gene in the developing and adult mouse. Neurosci. Lett. 282, 37-40.
66. Dunah, A. W., Jeong, H., Griffin, A., Kim, Y. M., Standaert, D. G., Hersch, S. M., Mouradian, M. M., Young, A. B., Tanese, N., and Krainc, D. (2002). Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease. Science 296, 2238-2243.
67. Duyao, M., Ambrose, C., Myers, R., Nov-elletto, A., Persichetti, F., Frontali, M., Folstein, S., Ross, C., Franz, M., Abbott, M., Gray, J., Conneally, P., Young, A., Penney, J., Hollingsworth, Z., Shoulson, I., Lazzarini, A., Falek, A., Koroshetz, W., Sax, D., Bird, E., Vonsattel, J., Bonilla, E., Alvir, J., Bickham Conde, J., Cha, J.-H., Dure, L., Gomez, F., Ramos, M., Sanchez-Ramos, J., Snodgrass, S., de Young, M., Wexler, N., Moscowitz, C., Penchaszadeh, G., MacFarlane, H., Anderson, M., Jenkins, B., Srinidhi, J., Barnes, G., Gusella, J., and Mac-Donald, M. (1993). Trinucleotide repeat length instability and age of onset in Huntington's disease. Nat. Genet. 4, 387-392.
68. Duyao, M. P., Auerbach, A. B., Ryan, A., Persichetti, F., Barnes, G. T., Mcneil, S. M., Ge, P.,Vonsattel, J. P., Gusella, J. F., Joyner, A. L., and MacDonald, M. E. (1995). Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269, 407-410.
69. Fan, J., Cowan, C. M., Zhang, L. Y., Hayden, M. R., and Raymond, L. A. (2009). Interaction of post-synaptic density protein-95 with NMDA receptors influences excito-toxicity in the yeast artificial chro-mosome mouse model of Hunt-ington's disease. J. Neurosci. 29, 10928-10938.
70. Fan, M. M., Fernandes, H. B., Zhang, L. Y., Hayden, M. R., and Raymond, L. A. (2007). Altered NMDA receptor trafficking in a yeast artificial chro-mosome transgenic mouse model of Huntington's disease. J. Neurosci. 27, 3768-3779.
71. Fedoroff, J. P., Peyser, C., Franz, M. L., and Folstein, S. E. (1994). Sexual disorders in Huntington's disease. J. Neuropsychiatry Clin. Neurosci. 6, 147-153.
72. Ferrante, R. J., Kowall, N. W., Beal, M. F., Martin, J. B., Bird, E. D., and Richardson, E. P. Jr. (1987). Mor-phologic and histochemical charac-teristics of a spared subset of stri-atal neurons in Huntington's dis-ease. J. Neuropathol. Exp. Neurol. 46, 12-27.
73. Ferrante, R. J., Kowall, N. W., Beal, M. F., Richardson, E. P. Jr., Bird, E. D., and Martin, J. B. (1985). Selective sparing of a class of striatal neurons in Huntington's disease. Science 230, 561-563.
74. Ferrante, R. J., Kowall, N. W., Cipol-loni, P. B., Storey, E., and Beal, M. F. (1993). Excitotoxin lesions in pri-mates as a model for Huntington's disease: histopathologic and neuro-chemical characterization. Exp. Neurol. 119, 46-71.
75. Ferrante, R. J., Kowall, N. W., and Richardson, E. P. Jr. (1991). Proliferative and degenerative changes in striatal spiny neurons in Hunt-ington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochem-istry. J. Neurosci. 11, 3877-3887.
76. Ferrante, R. J., Kubilus, J. K., Lee, J., Ryu, H., Beesen, A., Zucker, B., Smith, K., Kowall, N. W., Ratan, R. R., Luthi-Carter, R., and Her-sch, S. M. (2003). Histone deacety-lase inhibition by sodium butyrate chemotherapy ameliorates the neu-rodegenerative phenotype in Hunt-ington's disease mice. J. Neurosci. 23, 9418-9427.
77. Ferrer, I., Goutan, E., Marin, C., Rey, M. J., and Ribalta, T. (2000). Brain-derived neurotrophic factor in Huntington disease. Brain Res. 866, 257-261.
78. Folstein, S. E., Franz, M. L., Jensen, B. A., Chase, G. A., and Folstein, M. F. (1983). Conduct disorder and affec-tive disorder among the offspring of patients with Huntington's disease. Psychol. Med. 13, 45-52.
79. Gambardella, A., Muglia, M., Labate, A., Magariello, A., Gabriele, A. L., Mazzei, R., Pirritano, D., Conforti, F. L., Patitucci, A., Valentino, P., Zappia, M., and Quattrone, A. (2001). Juve-nile Huntington's disease presenting as progressive myoclonic epilepsy. Neurology 57, 708-711.
80. Garcia, M., Charvin, D., and Caboche, J. (2004). Expanded huntingtin activatesthe c-Jun terminal kinase/c-Jun pathway prior to aggregate formation in striatal neu-rons in culture. Neuroscience 127, 859-870.
81. Garcia, M., Vanhoutte, P., Pages, C., Besson, M. J., Brouillet, E., and Caboche, J. (2002). The mito-chondrial toxin 3-nitropropionic acid induces striatal neurodegen-eration via a c-Jun N-terminal kinase/c-Jun module. J. Neurosci. 22, 2174-2184.
82. Gardian, G., Browne, S. E., Choi, D. K., Klivenyi, P., Gregorio, J., Kubilus, J. K., Ryu, H., Langley, B., Ratan, R. R., Ferrante, R. J., and Beal, M. F. (2005). Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Hunt-ington's disease. J. Biol. Chem. 280, 556-563.
83. Gauthier, L. R., Charrin, B. C., Borrell-Pages, M., Dompierre, J. P., Rangone, H., Cordelieres, F. P., De Mey, J., Macdonald, M. E., Lessmann, V., Humbert, S., and Saudou, F. (2004). Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular trans-port along microtubules. Cell 118, 127-138.
84. Gharami, K., Xie, Y., An, J. J., Tonegawa, S., and Xu, B. (2008). Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Hunt-ington's disease phenotypes in mice. J. Neurochem. 105, 369-379.
85. Goldberg, Y. P., Rommens, J. M., Andrew, S. E., Hutchinson, G. B., Lin, B., Theilmann, J., Graham, R., Glaves, M. L., Starr, E., McDonald, H., Nasir, J., Schappert, K., Kalch-man, M. A., Clark, L. A., Hay-den, M. R. (1993). Identification of an Alu retrotransposition event in close proximity to a strong candi-date gene for Huntington's disease. Nature 362, 370-373.
86. Gong, B., Lim, M. C., Wanderer, J., Wyttenbach, A., and Morton, A. J. (2008). Time-lapse analysis of aggre-gate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death. Brain Res. Bull. 75, 146-157.
87. Gonzalez-Alegre, P., and Afifi, A. K. (2006). Clinical characteristics of childhood-onset (juvenile) Hunt-ington disease: report of 12 patients and review of the literature. J. Child Neurol. 21, 223-229.
88. Goto, S., Hirano, A., and Rojas-Corona, R. R. (1989). Immunohistochemical visualization of afferent nerve terminals in human globus pallidus and its alteration in neostriatal neu-rodegenerative disorders. Acta Neu-ropathol. 78, 543-550.
89. Grafton, S. T., Mazziotta, J. C., Pahl, J. J., St George-Hyslop, P., Haines, J. L., Gusella, J., Hoffman, J. M., Baxter, L. R., and Phelps M. E (1992). Serial changes of cerebral glucose metabo-lism and caudate size in persons at risk for Huntington's disease. Arch. Neurol. 49, 1161-1167.
90. Graham, R. K., Pouladi, M. A., Joshi, P., Lu, G., Deng, Y., Wu, N.-P., Figueroa, B. E., Metzler, M., André, V. M., Slow, E. J., Raymond, L., Friedlan-der, R., Levine, M. S., Leavitt, B. R., and Hayden, M. R. (2009). Dif-ferential susceptibility to excitotoxic stress in YAC128 mouse models of HD between initiation and pro-gression of disease. J. Neurosci. 29, 2193-2204.
91. Graveland, G. A., Williams, R. S., and DiFiglia, M. (1985). Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 227, 770-773.
92. Gu, X., Andre, V. M., Cepeda, C., Li, S. H., Li, X. J., Levine, M. S., and Yang, X. W. (2007). Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease. Mol. Neurodegener. 2, 8.
93. Gunawardena, S., Her, L. S., Brusch, R. G., Laymon, R. A., Niesman, I. R., Gordesky-Gold, B., Sintasath, L., Bonini, N. M., and Goldstein, L. S. (2003). Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40, 25-40.
94. Gutekunst, C. A., Li, S. H., Yi, H., Mul-roy, J. S., Kuemmerle, S., Jones, R., Rye, D., Ferrante, R. J., Hersch, S. M., and Li, X. J. (1999). Nuclear and neuropil aggregates in Huntington's disease: relationship to neuropathol-ogy. J. Neurosci. 19, 2522-2534.
95. Hamilton, J. M., Wolfson, T., Peavy, G. M., Jacobson, M. W., and Corey-Bloom, J. (2004). Rate and corre-lates of weight change in Hunting-ton's disease. J. Neurol. Neurosurg. Psychiatr. 75, 209-212.
96. Hardingham, G. E., Arnold, F. J., and Bading, H. (2001). Nuclear calcium signaling controls CREB-mediated gene expression triggered by synaptic activity. Nat. Neurosci. 4, 261-267.
97. Hardingham, G. E., and Bading, H. (2010). Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat. Rev. Neurosci. 11, 682-696.
98. Hardingham, G. E., Fukunaga, Y., and Bading, H. (2002). Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5, 405-414.
99. Harjes, P., and Wanker, E. E. (2003). The hunt for huntingtin function: interaction partners tell many differ-ent stories. Trends Biochem. Sci. 28, 425-433.
100. Harper, P. S. (1992). The epidemiol-ogy of Huntington's disease. Hum. Genet. 89, 365-376.
101. Heng, M. Y., Detloff, P. J., Wang, P. L., Tsien, J. Z., and Albin, R. L. (2009). In vivo evidence for NMDA receptor-mediated excito-toxicity in a murine genetic model of Huntington disease. J. Neurosci. 29, 3200-3205.
102. Herbst, M., and Wanker, E. E. (2007). Small molecule inducers of heat-shock response reduce polyQ-mediated huntingtin aggre-gation. A possible therapeutic strategy. Neurodegener. Dis. 4, 254-260.
103. Ho, A. K., Sahakian, B. J., Brown, R. G., Barker, R. A., Hodges, J. R., Ane, M. N., Snowden, J., Thompson, J., Esmonde, T., Gentry, R., Moore, J. W., and Bodner, T. (2003). Pro-file of cognitive progression in early Huntington's disease. Neurology 61, 1702-1706.
104. Hockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P. A., Steffan, J. S., Marsh, J. L., Thompson, L. M., Lewis, C. M., Marks, P. A., and Bates, G. P. (2003). Suberoylanilide hydroxamic acid, a histone deacety-lase inhibitor, ameliorates motor deficits in a mouse model of Hunt-ington's disease. Proc. Natl. Acad. Sci. U.S.A. 100, 2041-2046.
105. Hodges, J. R., Salmon, D. P., and Butters, N. (1990). Differential impairment of semantic and episodic memory in Alzheimer's and Huntington's dis-eases: a controlled prospective study. J. Neurol. Neurosurg. Psychiatr. 53, 1089-1095.
106. Hoffner, G., Island, M. L., and Djian, P. (2005). Purification of neuronal inclusions of patients with Hunting-ton's disease reveals a broad range of N-terminal fragments of expanded huntingtin and insoluble polymers. J. Neurochem. 95, 125-136.
107. Huang, C. C., Faber, P. W., Persichetti, F., Mittal, V., Vonsattel, J. P., Macdonald, M. E., and Gusella, J. F. (1998). Amyloid formation by mutant hunt-ingtin: threshold, progressivity and recruitment of normal polygluta-mine proteins. Somat. Cell Mol. Genet. 24, 217-233.
108. Hunter, J. M., Lesort, M., and Johnson, G. V. (2007). Ubiquitin-proteasome system alterations in a striatal cell model of Huntington's disease. J. Neurosci. Res. 85, 1774-1788.
109. Jakel, R. J., and Maragos, W. F. (2000). Neuronal cell death in Huntington's disease: a potential role for dopamine. Trends Neurosci. 23, 239-245.
110. Jana, N. R., Tanaka, M., Wang, G., and Nukina, N. (2000). Polyglutamine length-dependent interac-tion of Hsp40 and Hsp70 fam-ily chaperones with truncated N-terminal huntingtin: their role in suppression of aggregation and cel-lular toxicity. Hum. Mol. Genet. 9, 2009-2018.
111. Jana, N. R., Zemskov, E. A., Wang, G., and Nukina, N. (2001). Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal huntingtininducesapoptosis by caspase activation through mitochondrialcytochromec release. Hum. Mol. Genet. 10, 1049-1059.
112. Jankovic, J., Beach, J., and Ashizawa, T. (1995). Emotional and functional impact of DNA testing on patients with symptoms of Hunt-ington's disease. J. Med. Genet. 32, 516-518.
113. Jenkins, B. G., Koroshetz, W. J., Beal, M. F., and Rosen, B. R. (1993). Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 43, 2689-2695.
114. Jenkins, B. G., Rosas, H. D., Chen, Y. C., Makabe, T., Myers, R., Macdonald, M., Rosen, B. R., Beal, M. F., and Koroshetz, W. J. (1998). 1H NMR spectroscopy studies of Hunt-ington's disease: correlations with CAG repeat numbers. Neurology 50, 1357-1365.
115. Jensen, P., Fenger, K., Bolwig, T. G., and Sorensen, S. A. (1998). Crime in Huntington's disease: a study of registered offences among patients, relatives, and controls. J. Neurol. Neurosurg. Psychiatr. 65, 467-471.
116. Jocoy, E. L., Andre, V. M., Cummings, D. M., Rao, S. P., Wu, N., Ramsey, A. J., Caron, M. G., Cepeda, C., and Levine, M. S. (2011). Dissect-ing the contribution of individual receptor subunits to the enhance-ment of N-methyl-d-aspartate cur-rents by dopamine D1 receptor acti-vation in striatum. Front. Syst. Neuro. Sci. 5-28. doi: 10.3389/fnsys.2011.00004
117. Kaltschmidt, B., Widera, D., and Kaltschmidt, C. (2005). Signaling via NF-kappaB in the nervous sys-tem. Biochim. Biophys. Acta 1745, 287-299.
118. Kaminosono, S., Saito, T., Oyama, F., Ohshima, T., Asada, A., Nagai, Y., Nukina, N., and Hisanaga, S. (2008). Suppression of mutant Huntingtin aggregate formation by Cdk5/p35 through the effect on microtubule stability. J. Neurosci. 28, 8747-8755.
119. Karpuj, M. V., Garren, H., Slunt, H., Price, D. L., Gusella, J., Becher, M. W., and Steinman, L. (1999). Trans-glutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. Proc. Natl. Acad. Sci. U.S.A. 96, 7388-7393.
120. Kazantsev, A., Preisinger, E., Dranovsky, A., Goldgaber, D., and Housman, D. (1999). Insoluble detergent-resistant aggregates form between pathologi-cal and nonpathological lengths of polyglutamine in mammalian cells. Proc. Natl. Acad. Sci. U.S.A. 96, 11404-11409.
121. Kegel, K. B., Meloni, A. R., Yi, Y., Kim, Y. J., Doyle, E., Cuiffo, B. G., Sapp, E., Wang, Y., Qin, Z. H., Chen, J. D., Nevins, J. R., Aronin, N., and DiFiglia, M. (2002). Hunt-ingtin is present in the nucleus, inter-acts with the transcriptional core-pressor C-terminal binding protein, and represses transcription. J. Biol. Chem. 277, 7466-7476.
122. Kegel, K. B., Sapp, E., Yoder, J., Cuiffo, B., Sobin, L., Kim, Y. J., Qin, Z. H., Hayden, M. R., Aronin, N., Scott, D. L., Isenberg, G., Goldmann, W. H., and DiFiglia, M. (2005). Huntingtin associates with acidic phospholipids at the plasma membrane. J. Biol. Chem. 280, 36464-36473.
123. Kenney, C., Powell, S., and Jankovic, J. (2007). Autopsy-proven Huntington's disease with 29 trinu-cleotide repeats. Mov. Disord. 22, 127-130.
124. Kerbeshian, J., Burd, L., Leech, C., and Rorabaugh, A. (1991). Huntington disease and childhood-onset Tourette syndrome. Am. J. Med. Genet. 39, 1-3.
125. Kiechle, T., Dedeoglu, A., Kubilus, J., Kowall, N. W., Beal, M. F., Friedlander, R. M., Hersch, S. M., and Ferrante, R. J. (2002). Cytochrome C and caspase-9 expression in Huntington's disease. Neuromolecu-lar Med. 1, 183-195.
126. Kim, M. O., Chawla, P., Overland, R. P., Xia, E., Sadri-Vakili, G., and Cha, J. H. (2008). Altered his-tone monoubiquitylation mediated by mutant huntingtin induces tran-scriptional dysregulation. J. Neu-rosci. 28, 3947-3957.
127. Kirkwood, S. C., Siemers, E., Viken, R., Hodes, M. E., Conneally, P. M., Christian, J. C., and Foroud, T. (2002). Longitudinal person-ality changes among presympto-matic Huntington disease gene car-riers. Neuropsychiatry Neuropsychol. Behav. Neurol. 15, 192-197.
128. Kremer, B., Weber, B., and Hayden, M. R. (1992). New insights into the clinical features, pathogenesis and molecu-lar genetics of Huntington disease. Brain Pathol. 2, 321-335.
129. Kuhn, A., Goldstein, D. R., Hodges, A., Strand, A. D., Sengstag, T., Kooperberg, C., Becanovic, K., Pouladi, M. A., Sathasivam, K., Cha, J. H., Han-nan, A. J., Hayden, M. R., Leav-itt, B. R., Dunnett, S. B., Fer-rante, R. J., Albin, R., Shelbourne, P., Delorenzi, M., Augood, S. J., Faull, R. L., Olson, J. M., Bates, G. P., Jones, L., and Luthi-Carter, R. (2007). Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant hunt-ingtin length or wild-type hunt-ingtin dosage. Hum. Mol. Genet. 16, 1845-1861.
130. Kuppenbender, K. D., Standaert, D. G., Feuerstein, T. J., Penney, J. B. Jr., Young, A. B., and Landwehrmeyer, G. B. (2000). Expression of NMDA receptor subunit mRNAs in neu-rochemically identified projection and interneurons in the human striatum. J. Comp. Neurol. 419, 407-421.
131. Kuwert, T., Lange, H. W., Boecker, H., Titz, H., Herzog, H., Aulich, A., Wang, B. C., Nayak, U., and Feinen-degen, L. E. (1993). Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease. J. Neurol. 241, 31-36.
132. Landwehrmeyer, G. B., Standaert, D. G., Testa, C. M., Penney, J. B. Jr., and Young, A. B. (1995). NMDA receptor subunit mRNA expression by projection neurons and interneu-rons in rat striatum. J. Neurosci. 15, 5297-5307.
133. Lange, H., Thorner, G., Hopf, A., and Schroder, K. F. (1976). Morphometric studies of the neuropathologi-cal changes in choreatic diseases. J. Neurol. Sci. 28, 401-425.
134. Lee, W. C., Yoshihara, M., and Littleton, J. T. (2004). Cytoplasmic aggregates trap polyglutamine-containing pro-teins and block axonal transport in a Drosophila model of Huntington's disease. Proc. Natl. Acad. Sci. U.S.A. 101, 3224-3229.
135. Lesort, M., Chun, W., Johnson, G. V., and Ferrante, R. J. (1999). Tissue transglutaminase is increased in Huntington's disease brain. J. Neu-rochem. 73, 2018-2027.
136. Levine, M. S., Klapstein, G. J., Kop-pel, A., Gruen, E., Cepeda, C., Vargas, M. E., Jokel, E. S., Carpen-ter, E. M., Zanjani, H., Hurst, R. S., Efstratiadis, A., Zeitlin, S., and Chesselet, M. F. (1999). Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Hunting-ton's disease. J. Neurosci. Res. 58, 515-532.
137. Li, H., Li, S. H., Johnston, H., Shelbourne, P. F., and Li, X. J. (2000). Amino-terminal fragments of mutant huntingtin show selec-tive accumulation in striatal neurons and synaptic toxicity. Nat. Genet. 25, 385-389.
138. Li, H., Li, S. H., Yu, Z. X., Shelbourne, P., and Li, X. J. (2001). Huntingtin aggregate-associated axonal degen-eration is an early pathological event in Huntington's disease mice. J. Neu-rosci. 21, 8473-8481.
139. Li, S. H., Cheng, A. L., Zhou, H., Lam, S., Rao, M., Li, H., and Li, X. J. (2002). Interaction of Huntington disease protein with transcriptional activator Sp1. Mol. Cell. Biol. 22, 1277-1287.
140. Li, S. H., and Li, X. J. (2004). Huntingtin-proteininteractions and the pathogenesis of Hunt-ington's disease. Trends Genet. 20, 146-154.
141. Liévens, J. C., Rival, T., Iche, M., Chnei-weiss, H., and Birman, S. (2006). Expanded polyglutamine peptides disrupt EGF receptor signaling and glutamate transporter expression in Drosophila. Hum. Mol. Gen. 14, 713-724.
142. Liévens, J. C., Woodman, B., Mahal, A., Spasic-Boscovic, O., Samuel, D., Kerkerian-Le Goff, L., and Bates, G. P. (2001). Impaired glutamate uptake in the R6 Huntington's dis-ease transgenic mice. Neurobiol. Dis. 8, 807-821.
143. Lin, J., Wu, P. H., Tarr, P. T., Linden-berg, K. S., St-Pierre, J., Zhang, C. Y. (2004). Defects in adap-tive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119, 121-135.
144. Lipsky, R. H., Xu, K., Zhu, D., Kelly, C., Terhakopian, A., Novelli, A., and Marini, A. M. (2001). Nuclear fac-tor kappaB is a critical determinant in N-methyl-D-aspartate receptor-mediated neuroprotection. J. Neu-rochem. 78, 254-264.
145. Liu, Y., Wong, T. P., Aarts, M., Rooy-akkers, A., Liu, L., Lai, T. W., Wu, D. C., Lu, J., Tymianski, M., Craig, A. M., and Wang, Y. T. (2007). NMDA receptor subunits have differential roles in mediating excitotoxic neu-ronal death both in vitro and in vivo. J. Neurosci. 27, 2846-2857.
146. Luo, S., Vacher, C., Davies, J. E., and Rubinsztein, D. C. (2005). Cdk5 phosphorylation of hunt-ingtin reduces its cleavage by cas-pases: implications for mutant hunt-ingtin toxicity. J. Cell Biol. 169, 647-656.
147. Luthi-Carter, R., Strand, A., Peters, N. L., Solano, S. M., Hollingsworth, Z. R., Menon, A. S., Frey, A. S., Spek-tor, B. S., Penney, E. B., Schilling, G., Ross, C. A., Borchelt, D. R., Tap-scott, S. J., Young, A. B., Cha, J. H., and Olson, J. M. (2000). Decreased expression of striatal signaling genes in a mouse model of Hunting-ton's disease. Hum. Mol. Genet. 9, 1259-1271.
148. Luthi-Carter, R., Strand, A. D., Hanson, S. A., Kooperberg, C., Schilling, G., La Spada, A. R., Merry, D. E., Young, A. B., Ross, C. A., Borchelt, D. R., and Olson, J. M. (2002). Polygluta-mine and transcription: gene expres-sion changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum. Mol. Genet. 11, 1927-1937.
149. Lynch, G., Kramar, E. A., Rex, C. S., Jia, Y., Chappas, D., Gall, C. M., and Simmons, D. A. (2007). Brain-derived neurotrophic factor restores synap-tic plasticity in a knock-in mouse model of Huntington's disease. J. Neurosci. 27, 4424-4434.
150. Martel, M. A., Wyllie, D. J., and Hard-ingham, G. E. (2009). In developing hippocampal neurons, NR2B-containing N-methyl-D-aspartate receptors (NMDARs) can mediate signaling to neuronal survival and synaptic potentiation, as well as neuronal death. Neuroscience 158, 334-343.
151. Martin, E., Betuing, S., Pages, C., Cam-bon, K., Auregan, G., Deglon, N., Roze, E., and Caboche, J. (2011). Mitogen-and stress-activated pro-tein kinase 1-induced neuroprotec-tion in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter. Hum. Mol. Genet. 20, 2422-2434.
152. Martindale, D., Hackam, A., Wiec-zorek, A., Ellerby, L., Wellington, C., Mccutcheon, K., Singaraja, R., Kazemi-Esfarjani, P., Devon, R., Kim, S. U., Bredesen, D. E., Tufaro, F., and Hayden, M. R. (1998). Length of huntingtin and its polyglutamine tract influences localization and fre-quency of intracellular aggregates. Nat. Genet. 18, 150-154.
153. Martinez-Mir, M. I., Probst, A., and Palacios, J. M. (1991). Adenosine A2 receptors: selective localization in the human basal ganglia and alter-ations with disease. Neuroscience 42, 697-706.
154. Mazarei, G., Neal, S. J., Becanovic, K., Luthi-Carter, R., Simpson, E. M., and Leavitt, B. R. (2010). Expression analysis of novel striatal-enriched genes in Huntington disease. Hum. Mol. Genet. 19, 609-622.
155. McConoughey, S. J., Basso, M., Niatset-skaya, Z. V., Sleiman, S. F., Smirnova, N. A., Langley, B. C., Mahishi, L., Cooper, A. J., Antonyak, M. A., Cerione, R. A., Li, B., Starkov, A., Chaturvedi, R. K., Beal, M. F., Cop-pola, G., Geschwind, D. H., Ryu, H., Xia, L., Iismaa, S. E., Pallos, J., Paster-nack, R., Hils, M., Fan, J., Raymond, L. A., Marsh, J. L., Thompson, L. M., and Ratan, R. R. (2010). Inhi-bition of transglutaminase 2 mit-igates transcriptional dysregulation in models of Huntington disease. EMBO Mol. Med. 2, 349-370.
156. Meffert, M. K., and Baltimore, D. (2005). Physiological functions for brain NF-kappaB. Trends Neurosci. 28, 37-43.
157. Mendez, M. F. (2000). Mania in neuro-logic disorders. Curr. Psychiatry Rep. 2, 440-445.
158. Metzler, M., Gan, L., Mazarei, G., Gra-ham, R. K., Liu, L., Bissada, N., Lu, G., Leavitt, B. R., and Hayden, M. R. (2010). Phosphorylation of huntingtin at Ser421 in YAC128 neu-rons is associated with protection of YAC128 neurons from NMDA-mediated excitotoxicity and is mod-ulated by PP1 and PP2A. J. Neurosci. 30, 14318-14329.
159. Metzler, M., Gan, L., Wong, T. P., Liu, L., Helm, J., Liu, L., Georgiou, J., Wang, Y., Bissada, N., Cheng, K., Roder, J. C., Wang, Y. T., and Hayden, M. R. (2007). NMDA receptor function and NMDA receptor-dependent phosphorylation of huntingtin is altered by the endocytic protein HIP1. J. Neurosci. 27, 2298-2308.
160. Milnerwood, A. J., Gladding, C. M., Pouladi, M. A., Kaufman, A. M., Hines, R. M., Boyd, J. D., Ko, R. W., Vasuta, O. C., Graham, R. K., Hay-den, M. R., Murphy, T. H., and Ray-mond, L. A. (2010). Early increase in extrasynaptic NMDA receptor sig-naling and expression contributes to phenotype onset in Huntington's disease mice. Neuron 65, 178-190.
161. Mitra, S., Tsvetkov, A. S., and Finkbeiner, S. (2009). Single neuron ubiquitin-proteasome dynamics accompany-ing inclusion body formation in huntington disease. J. Biol. Chem. 284, 4398-4403.
162. Mochel, F., Charles, P., Seguin, F., Bar-ritault, J., Coussieu, C., Perin, L., Le Bouc, Y., Gervais, C., Carce-lain, G., Vassault, A., Feingold, J., Rabier, D., and Durr, A. (2007). Early energy deficit in Huntington dis-ease: identification of a plasma bio-marker traceable during disease pro-gression. PLoS ONE 2, e647. doi: 10.1371/journal.pone.0000647
163. Mochel, F., and Haller, R. G. (2011). Energy deficit in Huntington dis-ease: why it matters. J. Clin. Invest. 121, 493-499.
164. Morfini, G. A., You, Y. M., Pollema, S. L., Kaminska, A., Liu, K., Yoshioka, K., Bjorkblom, B., Coffey, E. T., Bagnato, C., Han, D., Huang, C. F., Banker, G., Pigino, G., and Brady, S. T. (2009). Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin. Nat. Neurosci. 12, 864-871.
165. Morton, A. J., Wood, N. I., Hastings, M. H., Hurelbrink, C., Barker, R. A., and Maywood, E. S. (2005). Disintegra-tion of the sleep-wake cycle and cir-cadian timing in Huntington's dis-ease. J. Neurosci. 25, 157-163.
166. Myers, R. H., Macdonald, M. E., Koroshetz, W. J., Duyao, M. P., Ambrose, C. M., Taylor, S. A., Barnes, G., Srinidhi, J., Lin, C. S., Whaley, W. L., Lazzarini, A. M., Schwarz, M., Wolff, G., Bird, E. D., Vonsattel, J.-P. G., and Gusella, J. F. (1993). De novo expansion of a (CAG)n repeat in sporadic Huntington's disease. Nat. Genet. 5, 168-173.
167. Nekooki-Machida, Y., Kurosawa, M., Nukina, N., Ito, K., Oda, T., and Tanaka, M. (2009). Distinct confor-mations of in vitro and in vivo amy-loids of huntingtin-exon1 show dif-ferent cytotoxicity. Proc. Natl. Acad. Sci. U.S.A. 106, 9679-9684.
168. Nucifora, F. C. Jr., Sasaki, M., Peters, M. F., Huang, H., Cooper, J. K., Yamada, M., Takahashi, H., Tsuji, S., Tron-coso, J., Dawson, V. L., Dawson, T. M., and Ross, C. A. (2001). Inter-ference by huntingtin and atrophin 1 with cbp-mediated transcription leading to cellular toxicity. Science 291, 2423-2428.
169. Ohyama, T., Verstreken, P., Ly, C. V., Rosenmund, T., Rajan, A., Tien, A. C., Haueter, C., Schulze, K. L., and Bellen, H. J. (2007). Huntingtin-interacting protein 14, a palmi-toyl transferase required for exo-cytosis and targeting of CSP to synaptic vesicles. J. Cell Biol. 179, 1481-1496.
170. Okamoto, S., Pouladi, M. A., Talantova, M., Yao, D., Xia, P., Ehrnhoefer, D. E., Zaidi, R., Clemente, A., Kaul, M., Graham, R. K., Zhang, D., Vincent Chen, H. S., Tong, G., Hayden, M. R., and Lipton, S. A. (2009). Balance between synaptic versus extrasynap-tic NMDA receptor activity influ-ences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 15, 1407-1413.
171. Ordway, J. M., Tallaksen-Greene, S., Gutekunst, C. A., Bernstein, E. M., Cearley, J. A., Wiener, H. W., Dure, L. S. T., Lindsey, R., Hersch, S. M., Jope, R. S., Albin, R. L., and Detloff, P. J. (1997). Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neuro-logical phenotype in the mouse. Cell 91, 753-763.
172. Pallos, J., Bodai, L., Lukacsovich, T., Pur-cell, J. M., Steffan, J. S., Thompson, L. M., and Marsh, J. L. (2008). Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum. Mol. Genet. 17, 3767-3775.
173. Paoletti, P., Vila, I., Rife, M., Lizcano, J. M., Alberch, J., and Gines, S. (2008). Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5. J. Neurosci. 28, 10090-10101.
174. Papadia, S., Soriano, F. X., Leveille, F., Martel, M. A., Dakin, K. A., Hansen, H. H., Kaindl, A., Sifringer, M., Fowler, J. (2008). Synap-tic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat. Neurosci. 11, 476-487.
175. Paradisi, I., Hernandez, A., and Arias, S. (2008). Huntington disease mutation in Venezuela: age of onset, haplotype analyses and geographic aggregation. J. Hum. Genet. 53, 127-135.
176. Patzold, T., and Brune, M. (2002). Obsessive compulsive disorder in Huntington disease: a case of iso-lated obsessions successfully treated with sertraline. Neuropsychiatry Neuropsychol. Behav. Neurol. 15, 216-219.
177. Paulsen, J. S., Ready, R. E., Hamil-ton, J. M., Mega, M. S., and Cummings, J. L. (2001). Neuropsychi-atric aspects of Huntington's disease. J. Neurol. Neurosurg. Psychiatr. 71, 310-314.
178. Peinemann, A., Schuller, S., Pohl, C., Jahn, T., Weindl, A., and Kassubek, J. (2005). Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J. Neurol. Sci. 239, 11-19.
179. Penney, J. B. Jr., Young, A. B., Shoulson, I., Starosta-Rubenstein, S., Snodgrass, S. R., Sanchez-Ramos, J., Ramos-Arroyo, M., Gomez, F., Pen-chaszadeh, G., Alvir, J., Esteves, J., DeQuiroz, I., Marsol, N., Moreno, H., Conneally, P. M., Bonilla, E., Wexler, N. S. (1990). Hunting-ton's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov. Disord. 5, 93-99.
180. Perrin, V., Regulier, E., Abbas-Terki, T., Hassig, R., Brouillet, E., Aebischer, P., Luthi-Carter, R., and Deglon, N. (2007). Neuroprotection by Hsp104 and Hsp27 in lentiviral-based rat models of Huntington's disease. Mol. Ther. 15, 903-911.
181. Perutz, M. F., Pope, B. J., Owen, D., Wanker, E. E., and Scherzinger, E. (2002). Aggregation of proteins with expanded glutamine and alanine repeats of the glutamine-rich and asparagine-rich domains of Sup35 and of the amyloid beta-peptide of amyloid plaques. Proc. Natl. Acad. Sci. U.S.A. 99, 5596-5600.
182. Petersen, A. A., Larsen, K. E., Behr, G. G., Romero, N., Przedborski, S., Brundin, P., and Sulzer, D. (2001). Brain-derived neurotrophic factor inhibits apoptosis and dopamine-induced free radical production in striatal neurons but does not pre-vent cell death. Brain Res. Bull. 56, 331-335.
183. Pflanz, S., Besson, J. A., Ebmeier, K. P., and Simpson, S. (1991). The clinical manifestation of mental disorder in Huntington's disease: a retrospec-tive case record study of disease pro-gression. Acta Psychiatr. Scand. 83, 53-60.
184. Pillon, B., Deweer, B., Agid, Y., and Dubois, B. (1993). Explicit memory in Alzheimer's, Huntington's, and Parkinson's diseases. Arch. Neurol. 50, 374-379.
185. Pillon, B., Deweer, B., Michon, A., Malapani, C., Agid, Y., and Dubois, B. (1994). Are explicit memory disorders of progressive supranu-clear palsy related to damage to striatofrontal circuits? Comparison with Alzheimer's, Parkinson's, and Huntington's diseases. Neurology 44, 1264-1270.
186. Quinn, N., and Schrag, A. (1998). Hunt-ington's disease and other choreas. J. Neurol. 245, 709-716.
187. Rammes, G., Zieglgansberger, W., and Parsons, C. G. (2008). The fraction of activated N-methyl-D-aspartate receptors during synaptic trans-mission remains constant in the presence of the glutamate release inhibitor riluzole. J. Neural Transm. 115, 1119-1126.
188. Ranen, N. G., Stine, O. C., Abbott, M. H., Sherr, M., Codori, A. M., Franz, M. L., Chao, N. I., Chung, A. S., Pleas-ant, N., Callahan, C., Kasch, L. M., Ghaffari, M., Chase, G. A., Kazazian, H. H., Brandt, J., Folstein, S. E., and Ross, C. A. (1995). Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Hunt-ington disease. Am. J. Hum. Genet. 57, 593-602.
189. Ravache, M., Weber, C., Merienne, K., and Trottier, Y. (2010). Transcriptional activation of REST by Sp1 in Huntington's disease models. PLoS ONE 5, e14311. doi: 10.1371/jour-nal.pone.0014311
190. Ravikumar, B., Berger, Z., Vacher, C., O'Kane, C. J., and Rubinsztein, D. C. (2006). Rapamycin pre-treatment protects against apoptosis. Hum. Mol. Genet. 15, 1209-1216.
191. Reynolds, D. S., Carter, R. J., and Mor-ton, A. J. (1998). Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington's dis-ease. J. Neurosci. 18, 10116-10127.
192. Reynolds, N. (2008). Re: autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov. Disord. 23, 1795-1796.
193. Richfield, E. K., and Herkenham, M. (1994). Selective vulnerability in Huntington's disease: preferential loss of cannabinoid receptors in lat-eral globus pallidus. Ann. Neurol. 36, 577-584.
194. Richfield, E. K., O'Brien, C. F., Eskin, T., and Shoulson, I. (1991). Heterogeneous dopamine receptor changes in early and late Hunt-ington's disease. Neurosci. Lett. 132, 121-126.
195. Roche, K. W., Standley, S., Mccallum, J., Dune Ly, C., Ehlers, M. D., and Wenthold, R. J. (2001). Molecu-lar determinants of NMDA recep-tor internalization. Nat. Neurosci. 4, 794-802.
196. Rockabrand, E., Slepko, N., Pantalone, A., Nukala, V. N., Kazantsev, A., Marsh, J. L., Sullivan, P. G., Steffan, J. S., Sensi, S. L., and Thompson, L. M. (2007). The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum. Mol. Genet. 16, 61-77.
197. Rosenblatt, A., and Leroi, I. (2000). Neu-ropsychiatry of Huntington's disease and other basal ganglia disorders. Psychosomatics 41, 24-30.
198. Rothman, S. M., and Olney, J. W. (1995). Excitotoxicity and the NMDA receptor-still lethal after eight years. Trends Neurosci. 18, 57-58.
199. Roze, E., Betuing, S., Deyts, C., Marcon, E., Brami-Cherrier, K., Pages, C., Humbert, S., Meri-enne, K., and Caboche, J. (2008). Mitogen-and stress-activated pro-tein kinase-1 deficiency is involved in expanded-huntingtin-induced transcriptionaldysregulation and striatal death. FASEB J. 22, 1083-1093.
200. Runne, H., Kuhn, A., Wild, E. J., Pratyak-sha, W., Kristiansen, M., Isaacs, J. D., Regulier, E., Delorenzi, M., Tabrizi, S. J., and Luthi-Carter, R. (2007). Analysis of potential tran-scriptomic biomarkers for Hunting-ton's disease in peripheral blood. Proc. Natl. Acad. Sci. U.S.A. 104, 14424-14429.
201. Ryu, H., Lee, J., Hagerty, S. W., Soh, B. Y., Mcalpin, S. E., Cormier, K. A., Smith, K. M., and Ferrante, R. J. (2006). ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's dis-ease. Proc. Natl. Acad. Sci. U.S.A. 103, 19176-19181.
202. Sadri-Vakili, G., Bouzou, B., Benn, C. L., Kim, M. O., Chawla, P., Overland, R. P., Glajch, K. E., Xia, E., Qiu, Z., Hersch, S. M., Clark, T. W., Yohrling, G. J., and Cha, J. H. (2007). Histones associ-ated with downregulated genes are hypo-acetylated in Huntington's dis-ease models. Hum. Mol. Genet. 16, 1293-1306.
203. Sanberg, P. R., Calderon, S. F., Gior-dano, M., Tew, J. M., and Norman, A. B. (1989). The quinolinic acid model of Huntington's disease: loco-motor abnormalities. Exp. Neurol. 105, 45-53.
204. Sarkar, S., Perlstein, E. O., Imarisio, S., Pineau, S., Cordenier, A., Maglathlin, R. L., Webster, J. A., Lewis, T. A., O'Kane, C. J., Schreiber, S. L., and Rubinsztein, D. C. (2007). Small molecules enhance autophagy and reduce toxicity in Huntington's dis-ease models. Nat. Chem. Biol. 3, 331-338.
205. Saudou, F., Finkbeiner, S., Devys, D., and Greenberg, M. E. (1998). Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66.
206. Sawada, H., Ishiguro, H., Nishii, K., Yamada, K., Tsuchida, K., Takahashi, H., Goto, J., Kanazawa, I., and Nagatsu, T. (2007). Characterization of neuron-specific huntingtin aggre-gates in human huntingtin knock-in mice. Neurosci. Res. 57, 559-573.
207. Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G. P., Davies, S. W., Lehrach, H., and Wanker, E. E. (1997). Huntingtin-encoded polyg-lutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90, 549-558.
208. Semaka, A., Warby, S., Leavitt, B. R., and Hayden, M. R. (2008). Re: autopsy-proven Huntington's disease with 29 trinucleotide repeats. Mov. Disord. 23, 1794-1795
209. Seo, H., Sonntag, K. C., Kim, W., Cattaneo, E., and Isacson, O. (2007). Proteasome activator enhances sur-vival of Huntington's disease neu-ronal model cells. PLoS ONE 2, e238. doi: 10.1371/journal.pone.0000238
210. Seong, I. S., Woda, J. M., Song, J. J., Lloret, A., Abeyrathne, P. D., Woo, C. J., Gregory, G., Lee, J. M., Wheeler, V. C., Walz, T., Kingston, R. E., Gusella, J. F., Conlon, R. A., and Macdon-ald, M. E. (2010). Huntingtin facil-itates polycomb repressive complex 2. Hum. Mol. Genet. 19, 573-583.
211. Shimohata, T., Nakajima, T., Yamada, M., Uchida, C., Onodera, O., Naruse, S., Kimura, T., Koide, R., Nozaki, K., Sano, Y., Ishiguro, H., Sakoe, K., Ooshima, T., Sato, A., Ikeuchi, T., Oyake, M., Sato, T., Aoyagi, Y., Hozumi, I., Nagatsu, T. (2000). Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat. Genet. 26, 29-36.
212. Shiwach, R. S., and Norbury, C. G. (1994). A controlled psychiatric study of individuals at risk for Hunt-ington's disease. Br. J. Psychiatry 165, 500-505.
213. Siesling, S., Vegter-Van Der Vlis, M., and Roos, R. A. (1997). Juvenile Huntington disease in the Netherlands. Pediatr. Neurol. 17, 37-43.
214. Sinadinos, C., Burbidge-King, T., Soh, D., Thompson, L. M., Marsh, J. L., Wyttenbach, A., and Mudher, A. K. (2009). Live axonal transport disruption by mutant huntingtin fragments in Drosophila motor neuron axons. Neurobiol. Dis. 34, 389-395.
215. Sipione, S., Rigamonti, D., Valenza, M., Zuccato, C., Conti, L., Pritchard, J., Kooperberg, C., Olson, J. M., and Cattaneo, E. (2002). Early tran-scriptional profiles in huntingtin-inducible striatal cells by microar-ray analyses. Hum. Mol. Genet. 11, 1953-1965.
216. Slow, E. J., Graham, R. K., Osmand, A. P., Devon, R. S., Lu, G., Deng, Y., Pearson, J., Vaid, K., Bissada, N., Wetzel, R., Leavitt, B. R., and Hayden, M. R. (2005). Absence of behavioral abnormalities and neu-rodegeneration in vivo despite wide-spread neuronal huntingtin inclu-sions. Proc. Natl. Acad. Sci. U.S.A. 102, 11402-11407.
217. Snell, R. G., Macmillan, J. C., Cheadle, J. P., Fenton, I., Lazarou, L. P., Davies, P., Macdonald, M. E., Gusella, J. F., Harper, P. S., and Shaw, D. J. (1993). Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease. Nat. Genet. 4, 393-397.
218. Stack, E. C., Dedeoglu, A., Smith, K. M., Cormier, K., Kubilus, J. K., Bogdanov, M., Matson, W. R., Yang, L., Jenkins, B. G., Luthi-Carter, R., Kowall, N. W., Hersch, S. M., Beal, M. F., and Ferrante, R. J. (2007). Neuroprotective effects of synap-tic modulation in Huntington's dis-ease R6/2 mice. J. Neurosci. 27, 12908-12915.
219. Starling, A. J., Andre, V. M., Cepeda, C., De Lima, M., Chandler, S. H., and Levine, M. S. (2005). Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium block-ade occur early in development in the R6/2 mouse model of Hunting-ton's disease. J. Neurosci. Res. 82, 377-386.
220. Steffan, J. S., Bodai, L., Pallos, J., Poel-man, M., Mccampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y. Z., Greenwald, M., Kurokawa, R., Housman, D. E., Jackson, G. R., Marsh, J. L., and Thompson, L. M. (2001). Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration inDrosophila. Nature413, 739-743.
221. Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y. Z., Gohler, H., Wanker, E. E., Bates, G. P., Housman, D. E., and Thompson, L. M. (2000). The Hunt-ington's disease protein interacts with p53 and CREB-binding pro-tein and represses transcription. Proc. Natl. Acad. Sci. U.S.A. 97, 6763-6768.
222. Steigerwald, F., Schulz, T. W., Schenker, L. T., Kennedy, M. B., Seeburg, P. H., and Kohr, G.(2000). C-Terminal truncation of NR2A subunits impairs synaptic but not extrasynaptic localization of NMDA receptors. J. Neurosci. 20, 4573-4581.
223. Strand, A. D., Baquet, Z. C., Aragaki, A. K., Holmans, P., Yang, L., Cleren, C., Beal, M. F., Jones, L., Kooperberg, C., Olson, J. M., and Jones, K. R. (2007). Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor deple-tion plays a major role in stri-atal degeneration. J. Neurosci. 27, 11758-11768.
224. Strehlow, A. N., Li, J. Z., and Myers, R. M. (2007). Wild-type huntingtin participates in protein trafficking between the Golgi and the extracel-lular space. Hum. Mol. Genet. 16, 391-409.
225. Subramaniam, S., Sixt, K. M., Barrow, R., and Snyder, S. H. (2009). Rhes, a striatal specific protein, mediates mutant-huntingtin cytotoxicity. Sci-ence 324, 1327-1330.
226. Sugars, K. L., and Rubinsztein, D. C. (2003). Transcriptional abnormalitiesinHunting-ton disease. Trends Genet. 19, 233-238.
227. Suhr, S. T., Senut, M. C., Whitelegge, J. P., Faull, K. F., Cuizon, D. B., and Gage, F. H. (2001). Identities of sequestered proteins in aggregates from cells with induced polygluta-mine expression. J. Cell Biol. 153, 283-294.
228. Sun, Y., Savanenin, A., Reddy, P. H., and Liu, Y. F. (2001). Polyglutamine expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95. J. Biol. Chem. 276, 24713-24718.
229. Szebenyi, G., Morfini, G. A., Babcock, A., Gould, M., Selkoe, K., Stenoien, D. L., Young, M., Faber, P. W., Macdon-ald, M. E., Mcphaul, M. J., and Brady, S. T. (2003). Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 40, 41-52.
230. Tallaksen-Greene, S. J., Janiszewska, A., Benton, K., Ruprecht, L., and Albin, R. L. (2010). Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease. Exp. Neurol. 225, 402-407.
231. Tang, T. S., Chen, X., Liu, J., and Bezprozvanny, I. (2007). Dopaminergic signaling and striatal neurode-generation in Huntington's disease. J. Neurosci. 27, 7899-7910.
232. Tang, T. S., Guo, C., Wang, H., Chen, X., and Bezprozvanny, I. (2009). Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's dis-ease mouse model. J. Neurosci. 29, 1257-1266.
233. Tang, T. S., Tu, H., Orban, P. C., Chan, E. Y., Hayden, M. R., and Bezprozvanny, I. (2004). HAP1 facil-itates effects of mutant huntingtin on inositol 1,4,5-trisphosphate-induced Ca release in primary culture of striatal medium spiny neurons. Eur. J. Neurosci. 20, 1779-1787.
234. Taniura, H., Sng, J. C., and Yoneda, Y. (2007). Histone modifications in the brain. Neurochem. Int. 51, 85-91.
235. The Huntington Collaborative Research Group. (1993). A novel gene con-taining a trinucleotide repeat that is expanded and unstable on Hunting-ton's disease chromosomes. Cell 72, 971-983.
236. Thomas, E. A., Coppola, G., Desplats, P. A., Tang, B., Soragni, E., Burnett, R., Gao, F., Fitzgerald, K. M., Borok, J. F., Herman, D., Geschwind, D. H., and Gottesfeld, J. M. (2008). The HDAC inhibitor 4b ameliorates the disease phenotype and tran-scriptional abnormalities in Hunt-ington's disease transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 105, 15564-15569.
237. Thomas, E. A., Coppola, G., Tang, B., Kuhn, A., Kim, S., Geschwind, D. H., Brown, T. B., Luthi-Carter, R., and Ehrlich, M. E. (2011). In vivo cell-autonomous transcriptional abnor-malities revealed in mice expressing mutant huntingtin in striatal but not cortical neurons. Hum. Mol. Genet. 20, 1049-1060.
238. Thompson, P. D., Bhatia, K. P., Brown, P., Davis, M. B., Pires, M., Quinn, N. P., Luthert, P., Honovar, M., O'Brien, M. D., Marsden, C. D., and Harding, A. E. (1994). Cortical myoclonus in Huntington's disease. Mov. Disord. 9, 633-641.
239. Tovar, K. R., and Westbrook, G. L. (1999). The incorporation of NMDA receptors with a distinct subunit composi-tion at nascent hippocampal synapses in vitro. J. Neurosci. 19, 4180-4188.
240. Trushina, E., Dyer, R. B., Badger, J. D., Ure, D., Eide, L., Tran, D. D., Vrieze, B. T., Legendre-Guillemin, V., Mcpherson, P. S., Mandavilli, B. S., Van Houten, B., Zeitlin, S., Mcniven, M., Aebersold, R., Hayden, M., Parisi, J. E., Seeberg, E., Dragatsis, I., Doyle, K., Bender, A., Chacko, C., and Mcmurray, C. T. (2004). Mutant huntingtin impairs axonal traffick-ing in mammalian neurons in vivo and in vitro. Mol. Cell. Biol. 24, 8195-8209.
241. Turner, C., Cooper, J. M., and Schapira, A. H. (2007). Clinical correlates of mitochondrial function in Hunting-ton's disease muscle. Mov. Disord. 22, 1715-1721.
242. Tydlacka, S., Wang, C. E., Wang, X., Li, S., and Li, X. J. (2008). Differentialactivitiesofthe ubiquitin-proteasome system in neurons versus glia may account for the preferential accumulation of misfolded proteins in neurons. J. Neurosci. 28, 13285-13295.
243. Vacher, C., Garcia-Oroz, L., and Rubin-sztein, D. C. (2005). Overexpression of yeast hsp104 reduces polygluta-mine aggregation and prolongs sur-vival of a transgenic mouse model of Huntington's disease. Hum. Mol. Genet. 14, 3425-3433.
244. Vanhoutte, P., and Bading, H. (2003). Opposing roles of synaptic and extrasynaptic NMDA receptors in neuronal calcium signalling and BDNF gene regulation. Curr. Opin. Neurobiol. 13, 366-371.
245. Venkatraman, P., Wetzel, R., Tanaka, M., Nukina, N., and Goldberg, A. L. (2004). Eukaryotic protea-somes cannot digest polyglutamine sequences and release them dur-ing degradation of polyglutamine-containing proteins. Mol. Cell 14, 95-104.
246. Verhoef, L. G., Lindsten, K., Masucci, M. G., and Dantuma, N. P. (2002). Aggregate formation inhibits pro-teasomal degradation of polygluta-mine proteins. Hum. Mol. Genet. 11, 2689-2700.
247. Videnovic, A., Leurgans, S., Fan, W., Jaglin, J., and Shannon, K. M. (2009). Daytime somnolence and noctur-nal sleep disturbances in Huntington disease. Parkinsonism Relat. Disord. 15, 471-474.
248. Vogel, C. M., Drury, I., Terry, L. C., and Young, A. B. (1991). Myoclonus in adult Huntington's disease. Ann. Neurol. 29, 213-215.
249. Vonsattel, J. P., Myers, R. H., Stevens, T. J., Ferrante, R. J., Bird, E. D., and Richardson, E. P. Jr. (1985). Neuropathological classification of Huntington's disease. J. Neuropathol. Exp. Neurol. 44, 559-577.
250. Wexler, N. S., Lorimer, J., Porter, J., Gomez, F., Moskowitz, C., Shackell, E., Marder, K., Penchaszadeh, G., Roberts, S. A., Gayan, J., Brocklebank, D., Cherny, S. S., Car-don, L. R., Gray, J., Dlouhy, S. R., Wiktorski, S., Hodes, M. E., Conneally, P. M., Penney, J. B., Gusella, J., Cha, J. H., Irizarry, M., Rosas, D., Hersch, S., Hollingsworth, Z., Macdonald, M., Young, A. B., Andresen, J. M., Housman, D. E., De Young, M. M., Bonilla, E., Still-ings, T., Negrette, A., Snodgrass, S. R., Martinez-Jaurrieta, M. D., Ramos-Arroyo, M. A., Bickham, J., Ramos, J. S., Marshall, F., Shoulson, I., Rey, G. J., Feigin, A., Arnheim, N., Acevedo-Cruz, A., Acosta, L., Alvir, J., Fischbeck, K., Thompson, L. M., Young, A., Dure, L., O'Brien, C. J., Paulsen, J., Brickman, A., Krch, D., Peery, S., Hogarth, P., Hig-gins, D. S. Jr., and Landwehrmeyer, B. (2004). Venezuelan kindreds reveal that genetic and environ-mental factors modulate Hunt-ington's disease age of onset. Proc. Natl. Acad. Sci. U.S.A. 101, 3498-3503.
251. Weydt, P., Pineda, V. V., Torrence, A. E., Libby, R. T., Satterfield, T. F., Lazarowski, E. R., Gilbert, M. L., Morton, G. J., Bammler, T. K., Strand, A. D., Cui, L., Beyer, R. P., Easley, C. N., Smith, A. C., Krainc, D., Luquet, S., Sweet, I. R., Schwartz, M. W., and La Spada, A. R. (2006). Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab. 4, 349-362.
252. Wheelock, V. L., Tempkin, T., Marder, K., Nance, M., Myers, R. H., Zhao, H., Kayson, E., Orme, C., and Shoulson, I. (2003). Predic-tors of nursing home placement in Huntington disease. Neurology 60, 998-1001.
253. Xie, Y., Hayden, M. R., and Xu, B. (2010). BDNF overexpression in the forebrain rescues Huntington's dis-ease phenotypes in YAC128 mice. J. Neurosci. 30, 14708-14718.
254. Yanai, A., Huang, K., Kang, R., Sin-garaja, R. R., Arstikaitis, P., Gan, L., Orban, P. C., Mullard, A., Cowan, C. M., Raymond, L. A., Dris-del, R. C., Green, W. N., Raviku-mar, B., Rubinsztein, D. C., El-Husseini, A., and Hayden, M. R. (2006). Palmitoylation of huntingtin by HIP14 is essential for its traffick-ing and function. Nat. Neurosci. 9, 824-831.
255. Yang, L., Mei, Q., Zielinska-Kwiatkowska, A., Matsui, Y., Blackburn, M. L., Benedetti, D., Krumm, A. A., Taborsky, G. J. Jr., and Chansky, H. A. (2003). An ERG (ets-related gene)-associated histone methyltransferase inter-acts with histone deacetylases 1/2 and transcription co-repressors mSin3A/B. Biochem. J. 369, 651-657.
256. Zeitlin, S., Liu, J. P., Chapman, D. L., Papaioannou, V. E., and Efstratiadis, A. (1995). Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 11, 155-163.
257. Zeron, M. M., Fernandes, H. B., Krebs, C., Shehadeh, J., Wellington, C. L., Leavitt, B. R., Baim-bridge, K. G., Hayden, M. R., and Raymond, L. A. (2004). Potentia-tion of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC trans-genic mouse model of Huntington's disease. Mol. Cell. Neurosci. 25, 469-479.
258. Zeron, M. M., Hansson, O., Chen, N., Wellington, C. L., Leavitt, B. R., Brundin, P., Hayden, M. R., and Raymond, L. A. (2002). Increased sensitivity to N-methyl-D-aspartate receptor-mediated exci-totoxicity in a mouse model of Huntington's disease. Neuron 33, 849-860.
259. Zhai, W., Jeong, H., Cui, L., Krainc, D., and Tjian, R. (2005). In vitro analysis of huntingtin-mediated transcrip-tional repression reveals multiple transcription factor targets. Cell 123, 1241-1253.
260. Zhang, H., Li, Q., Graham, R. K., Slow, E., Hayden, M. R., and Bezprozvanny, I. (2008). Full length mutant huntingtin is required for altered Ca2+ signaling and apop-tosis of striatal neurons in the YAC mouse model of Hunting-ton's disease. Neurobiol. Dis. 31, 80-88.
261. Zhang, S. J., Steijaert, M. N., Lau, D., Schutz, G., Delucinge-Vivier, C., Descombes, P., and Bading, H. (2007). Decoding NMDA receptor signaling: identification of genomic programs specifying neuronal sur-vival and death. Neuron 53, 549-562.
262. Zuccato, C., Belyaev, N., Conforti, P., Ooi, L., Tartari, M., Papadi-mou, E., Macdonald, M., Fossale, E., Zeitlin, S., Buckley, N., and Catta-neo, E. (2007). Widespread disrup-tion of repressor element-1 silenc-ing transcription factor/neuron-restrictive silencer factor occu-pancy at its target genes in Hunt-ington's disease. J. Neurosci. 27, 6972-6983.
263. Zuccato, C., and Cattaneo, E. (2009). Brain-derived neurotrophic factor in neurodegenerative diseases. Nat. Rev. Neurol. 5, 311-322.
264. Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., Macdonald, M. E., Friedlander, R. M., Silani, V., Hayden, M. R., Timmusk, T., Sipione, S., and Cat-taneo, E. (2001). Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 293, 493-498.
265. Zuccato, C., Tartari, M., Crotti, A., Goffredo, D., Valenza, M., Conti, L., Cataudella, T., Leavitt, B. R., Hayden, M. R., Timmusk, T., Rigamonti, D., and Cattaneo, E. (2003). Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 35, 76-83.
266. Zuhlke, C., Riess, O., Bockel, B., Lange, H., and Thies, U. (1993). Mitotic stability and meiotic variability of the (CAG)n repeat in the Huntington disease gene. Hum. Mol. Genet. 2, 2063-2067.